Mayne Pharma reported first-quarter underlying earnings before interest, tax, depreciation and amortisation of A$5.3 million, down 52% from A$11 million a year earlier, according to its October 26 ASX announcement.
Revenue for the three months ended September 30 fell 2% to A$95.7 million, while gross profit declined 8% to A$60.3 million.
The company attributed the weaker performance to lower dermatology sales after generic competition and other commercial pressures, alongside planned investment in its women’s health business.
The underlying measure excludes several costs. Reported EBITDA was a loss of A$1.6 million after A$6.9 million in non-recurring items. The figures are unaudited company results, released Monday morning in Australia.